Vanguard Group
CYT

Vanguard Group’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Vanguard Group’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-687,391
Closed -$2.09M – 4506
2023
Q4 		$2.09M Buy
687,391
+46,611
+7% +$141K ﹤0.01% 3587
2023
Q3 		$1.82M Buy
640,780
+55,997
+10% +$154K ﹤0.01% 3618
2023
Q2 		$1.52M Hold
584,783
– – ﹤0.01% 3756
2023
Q1 		$1.06M Hold
584,783
– – ﹤0.01% 3894
2022
Q4 		$965K Buy
584,783
+291
+0% +$467 ﹤0.01% 3927
2022
Q3 		$1.12M Sell
584,492
-27,106
-4% -$70.7K ﹤0.01% 3967
2022
Q2 		$1.83M Buy
611,598
+226,645
+59% +$579K ﹤0.01% 3840
2022
Q1 		$1.45M Buy
384,953
+41,720
+12% +$237K ﹤0.01% 4084
2021
Q4 		$3.9M Buy
343,233
+1,982
+0.6% +$30.2K ﹤0.01% 3746
2021
Q3 		$5.99M Buy
341,251
+271,251
+388% +$5.07M ﹤0.01% 3535
2021
Q2 		$1.5M Buy
+70,000
New +$1.31M ﹤0.01% 4049

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Vanguard Group's CYT Position: Q1 2024 in Review

Vanguard Group sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 687,391 shares — an estimated $2.09M sold.

Vanguard Group first reported a position in CYT in Q2 2021 and held it in 11 quarters. The position peaked at $5.99M in Q3 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Vanguard Group reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 687,391 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.09M.
  • Vanguard Group first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
  • Vanguard Group's Cyteir Therapeutics, Inc. Common Stock position peaked at $5.99M in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.